Repurposing anticancer drugs for COVID-19-induced inflammation, immune dysfunction, and coagulopathy

Kamal S. Saini, Carlo Lanza, Marco Romano, Evandro de Azambuja, Javier Cortes, Begoña de las Heras, Javier de Castro, Monika Lamba Saini, Sibylle Loibl, Giuseppe Curigliano, Chris Twelves, Manuela Leone, Mrinal M. Patnaik

Research output: Contribution to journalComment/debatepeer-review

2 Scopus citations

Abstract

Three cardinal manifestations of neoplasia, namely inflammation, immune dysfunction, and coagulopathy are also seen in patients with severe SARS-CoV-2 infection, providing a biological rationale for testing selected anticancer drugs for their ability to control the symptoms and/or modify the course of COVID-19.

Original languageEnglish (US)
Pages (from-to)694-697
Number of pages4
JournalBritish journal of cancer
Volume123
Issue number5
DOIs
StatePublished - Sep 1 2020

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Repurposing anticancer drugs for COVID-19-induced inflammation, immune dysfunction, and coagulopathy'. Together they form a unique fingerprint.

Cite this